Latest Recurring Revenue News

Micro-X has secured an eight-month, US$0.75 million contract extension from the US Department of Homeland Security to upgrade its miniature CT baggage scanner for scaled manufacturing. The award advances a technology platform towards possible commercial use, but does not yet represent a product sale or customer deployment.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

PaySauce has moved its Global Payroll Platform from development into commercial operation in Australia, while first-quarter FY27 ARR rose 8% to $9.5 million. The expansion is supported by a stronger cash position, but higher customer acquisition costs and lower profitability leave execution firmly in focus.

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

Elixinol Wellness will acquire personalised supplement platform Vitable for headline consideration of A$2.5 million in shares, adding recurring revenue and more than 7,850 active subscribers. The deal could lift combined revenue to A$27 million by 2028, but remains subject to shareholder approval and carries meaningful dilution risk.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Delorean Corporation and Opal have completed the concept stage for a proposed anaerobic digestion facility at Opal’s Maryvale Mill in Victoria. The project could replace natural gas used by the mill’s rotary lime kiln, but still requires further engineering, commercial work and a final investment decision.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

BluGlass has begun a three-to-five-month, A$286,000 feasibility collaboration with global photonics company Coherent to develop a novel gallium nitride device for scientific and medical applications. The agreement offers technical and commercial promise, but does not yet include a production commitment or confirmed product launch.

icetana AI has signed a five-year, $675,480 plus GST Antara Core contract with Millennium Services Group for deployment to one of Australia’s largest retail property groups. The deal is the third Antara Core sale in three months and is expected to add $135,096 to annual recurring revenue from 1 November 2026.